Charles Schwab
GBIO

Charles Schwab’s Generation Bio GBIO Stock Holding History

Charles Schwab’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,686
Closed -$75.8K – 3493
2025
Q2 		$75.8K Sell
23,686
-11,958
-34% -$46.1K ﹤0.01% 3426
2025
Q1 		$144K Sell
35,644
-1,059
-3% -$7.44K ﹤0.01% 3294
2024
Q4 		$389K Sell
36,703
-5,627
-13% -$100K ﹤0.01% 3210
2024
Q3 		$1.05M Buy
42,330
+869
+2% +$23K ﹤0.01% 2903
2024
Q2 		$1.17M Buy
41,461
+2,535
+7% +$82.4K ﹤0.01% 2870
2024
Q1 		$1.58M Buy
38,926
+778
+2% +$18.3K ﹤0.01% 2659
2023
Q4 		$629K Buy
38,148
+487
+1% +$8.49K ﹤0.01% 2987
2023
Q3 		$1.43M Sell
37,661
-691
-2% -$32.7K ﹤0.01% 2687
2023
Q2 		$2.11M Buy
38,352
+4,997
+15% +$229K ﹤0.01% 2533
2023
Q1 		$1.43M Sell
33,355
-1,276
-4% -$61.7K ﹤0.01% 2615
2022
Q4 		$1.36M Buy
34,631
+571
+2% +$30K ﹤0.01% 2677
2022
Q3 		$1.81M Buy
34,060
+2,203
+7% +$138K ﹤0.01% 2612
2022
Q2 		$2.09M Buy
31,857
+2,686
+9% +$176K ﹤0.01% 2559
2022
Q1 		$2.14M Sell
29,171
-2,687
-8% -$156K ﹤0.01% 2623
2021
Q4 		$2.26M Buy
31,858
+1,367
+4% +$239K ﹤0.01% 2667
2021
Q3 		$7.64M Buy
30,491
+11,102
+57% +$2.66M ﹤0.01% 2161
2021
Q2 		$5.22M Buy
19,389
+1,156
+6% +$346K ﹤0.01% 2330
2021
Q1 		$5.19M Buy
18,233
+9,973
+121% +$3.19M ﹤0.01% 2285
2020
Q4 		$2.34M Buy
8,260
+183
+2% +$58.7K ﹤0.01% 2549
2020
Q3 		$2.5M Buy
+8,077
New +$1.93M ﹤0.01% 2421

Other funds holding GBIO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charles Schwab's GBIO Position: Q3 2025 in Review

Charles Schwab sold out of Generation Bio (GBIO) in Q3 2025, closing a stake of 23,686 shares — an estimated $75.8K sold.

Charles Schwab first reported a position in GBIO in Q3 2020 and held it in 20 quarters. The position peaked at $7.64M in Q3 2021. 41 funds tracked by Wall St. Rank hold GBIO as of Q3 2025.

  • Charles Schwab reported no remaining Generation Bio position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 23,686 Generation Bio shares in Q3 2025, an estimated $75.8K.
  • Charles Schwab first reported a position in Generation Bio in Q3 2020 and held it in 20 quarters.
  • Charles Schwab's Generation Bio position peaked at $7.64M in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Generation Bio as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.